Assessment of hemostasis through the retrospectroscope [3]

Journal of Thrombosis and Haemostasis

Volumn 4, Issue 9, 2006, Pages 2074-2078

  Weiskopf, Richard B ^a,b  

^a NOVO NORDISK A S   (Denmark)

^b UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMINOCAPROIC ACID; ANTICOAGULANT AGENT; ANTIFIBRINOLYTIC AGENT; APROTININ; CREATININE; FIBRIN; FRESH FROZEN PLASMA; GENTAMICIN; INOTROPIC AGENT; PLACEBO; TRANEXAMIC ACID;

BLEEDING DISORDER; CARDIOPULMONARY BYPASS; CLINICAL ASSESSMENT TOOL; CLINICAL STUDY; CLINICAL TRIAL; CORONARY ARTERY BYPASS GRAFT; CREATININE CLEARANCE; DRUG SAFETY; ERYTHROCYTE TRANSFUSION; FIBRIN DEPOSITION; GLOMERULUS FILTRATION; HEMOSTASIS; HUMAN; KIDNEY DISEASE; KIDNEY DYSFUNCTION; LETTER; META ANALYSIS; NEPHROTOXICITY; NONHUMAN; PRIORITY JOURNAL; RETROSPECTIVE STUDY; SPECTROSCOPY; SURGICAL RISK; SYSTEMATIC REVIEW;

ANIMALS; APROTININ; HEMOSTASIS; HUMANS; RETROSPECTIVE STUDIES;

EID: 33747175370     PISSN: 15387933     EISSN: 15387836     Source Type: Journal    
DOI: 10.1111/j.1538-7836.2006.02145.x     Document Type: Letter

References (58)

1. Trasylol® (aprotinin injection). http://www.fda.gov/cder/foi/label/ 2006/020304s009lbl.pdf (Accessed 5 April 2006).
2. Zufferey P, Merguiol F, Laporte S, Decousus H, Mismetti P, Auboyer C, Sumama CM, Molliex S. Do anti-fibrinolytics reduce allogenic blood transfusion in orthopedic surgery?: A meta-analysis of randomized trials. Anesthesiology 2006; in press.
3. Weiskopf R. If you prick us, do we not bleed? Anesthesiology 2006; in press.
4. Levy JH. Aprotinin is useful as a hemostatic agent in cardiopulmonary surgery: Yes. J Thromb Haemost 2006; 4: 1875-8.
5. Karkouti K, Beattie WS. Aprotinin is useful as a hemostatic agent in cardiopulmonary surgery: No. J Thromb Haemost 2006; 4: 1879-81.
6. Karkouti K, Beattie W, Datillo K, McCluskey S, Ghannam M, Hamdy A, Wijeysundera D, Fedorko L, Yau T. A propensity score case-control comparison of aprotinin and tranexamic acid in high-transfusion-risk cardiac surgery. Transfusion 2006; 46: 327-38.
7. Mangano D, Tudor J, Dietzel C. The risk associated with aprotinin in cardiac surgery. N Engl J Med 2006; 354: 353-65.
8. Kincaid E, Ashburn D, Hoyle J, Reichert M, Hammon J, Kon N. Does the combination of aprotinin and angiotensis-converting enzyme inhibitor cause renal failure after cardiac surgery? Ann Thorac Surg 2005; 80: 1388-93.
9. D'Ambra MN, Akins CW, Blackstone EH, Bonney SL, Cohn LH, Cosgrove DM, Levy JH, Lynch KE, Maddi R. Aprotinin in primary valve replacement and reconstruction: A multicenter, double-blind, placebo-controlled trial. J Thorac Cardiovasc Surg 1996; 112: 1081-9.
10. Rosenbaum PR, Rubin DB. Reducing bias in observational studies using subclassification on the propensity score. J Am Stat Assoc 1984; 79: 516-24.
11. Rubin DB. Estimating causal effects from large data sets using propensity scores. Ann Intern Med 1997; 127: 757-63.
12. Comroe JH. Retrospectroscope. Insights into Medical Discovery. Menlo Park, CA, USA: Von Gehr Press, 1977.
13. Hébert PC, Wells G, Blajchman MA, Marshall J, Martin C, Pagliarello G, Tweeddale M, Schweitzer I, Yetisir E. A multicenter, randomized, controlled clinical trial of transfusion requirements in critical care. N Engl J Med 1999; 340: 409-17.
14. Hébert PC, Wells G, Tweedale M, Martin C, Marshall J, Pham B, Blajchman M, Schweitzer I, Pagliarello G. Does transfusion practice affect mortality in critically ill patients? Am J Respir Crit Care Med 1997; 155: 1618-23.
15. Stover E, Wiegel L, Parks R, Levin J, Body S, Maddi R, D'Ambra M, Mangano D, Spiess B. Variability in transfusion practice for coronary artery bypass surgery persists despite national consensus guidelines: A 24-institution study. Anesthesiology 1998; 88: 327-33.
16. Goodnough L, Johnston M, Toy P, Group TMAA. The variability of transfusion practice in coronary artery bypass surgery. JAMA 1991; 265: 86-90.
17. Hutton B, Fergusson D, Tinmouth A, McIntyre L, Kmetic A, Hebert P. Transfusion rates vary significantly amongst Canadian medical centers. Can J Anaesth 2005; 52: 581-90.
18. Hébert P, Wells G, Martin C, Tweeddale M, Marshall J, Blajchman M, Pagliarello G, Sandham D, Schweitzer I, Boisvert D, Calder L. Variation in red cell transfusion practice in the intensive care unit: A multicentre cohort study. Crit Care 1999; 3: 57-63.
19. Ott E, Moehnle P, Tudor C, Hsu P, Mangano D. CABG-Surgery in Europe and North America: Timelines and outcomes. Anesthesiology 2003; 99: A-254 (Abstract).
20. Just M, Erdmann G, Habermann E. The renal handling of polybasic drugs. 1. Gentamicin and aprotinin in intact animals. Naunyn Schmiedebergs Arch Pharmacol 1977; 300: 57-66.
21. Fritz H, Wunderer G. Biochemistry and applications of aprotinin, the kallikrein inhibitor from bovine organs. Arzneimittelforschung 1983; 33: 479-94.
22. Tenstad O, Williamson HE, Clausen G, Oien AH, Aukland K. Glomerular filtration and tubular absorption of the basic polypeptide aprotinin. Acta Physiol Scand 1994; 152: 33-50.
23. Moestrup SK, Cui S, Vorum H, Bregengard C, Bjorn SE, Norris K, Gliemann J, Christensen EI. Evidence that epithelial glycoprotein 330/megalin mediates uptake of polybasic drugs. J Clin Invest 1995; 96: 1404-13.
24. Morin NJ, Frau A, Nonclercq D, Toubeau G, Zanen J, Heuson-Stiennon JA, Bergeron MG, Beauchamp D, Laurent G. Potentiation of gentamicin nephrotoxicity in the rat by5infusion of aprotinin. Exp Mol Pathol 1994; 60: 197-213.
25. Bledsoe G, Crickman S, Mao J, Xia CF, Murakami H, Chao L, Chao J. Kallikrein/kinin protects against gentamicin-induced nephrotoxicity by inhibition of inflammation and apoptosis. Nephrol Dial Transplant 2006; 21: 624-33.
26. Sundt 3rd TM, Kouchoukos NT, Saffitz JE, Murphy SF, Wareing TH, Stahl DJ. Renal dysfunction and intravascular coagulation with aprotinin and hypothermic circulatory arrest. Ann Thorac Surg 1993; 55: 1418-24.
27. Fisher DF, Yawn DH, Crawford S. Preoperative disseminated intravascular coagulation associated with aortic aneurysms. Arch Surg 1983; 118: 1252-5.
28. Jalenska MM, Szmidt J, Bojakowski K, Grzela T, Palester-Chlebowczyk M. Compensated activation of coagulation in patients with abdominal aortic aneurysm: Effects of heparin treatment prior to elective surgery. Thromb Haemost 2004; 92: 997-1002.
29. Sakakibara Y, Takeda T, Hori M, Mitsui T, Ijima H. Disseminated intravascular coagulation in aortic aneurysms: Assessment of consumption site using labeled-platelet scintigraphy. Thorac Cardiovasc Surg 1999; 47: 162-5.
30. ten Cate JW, Timmers H, Becker AE. Coagulopathy in ruptured or dissecting aortic aneurysms. Am J Med 1975; 59: 17-6.
31. Smith CR, Mongero LB, DeRosa CM, Michler RE, Oz MC. Safety of aprotinin in profound hypothermia and circulatory arrest. Ann Thorac Surg 1994; 58: 606-7.
32. Kouchoukos NT, Sundt TM, Saffitz JE. In Reply. Ann Thorac Surg 1994; 58: 607-8.
33. Kramer H, Dusing R, Glanzer K, Kipnowski J, Klingmuller DHM-L. Effects of aprotinin on renal function. Contr Nephrol 1984; 42: 233-41.
34. Maier M, Starlinger M, Zhegu Z, Rana H, Binder BR. Effect of the protease inhibitor aprotinin on renal hemodynamics in the pig. Hypertension 1985; 7: 32-8.
35. Mangano CM, Diamondstone LS, Ramsay JG, Aggarwal A, Herskowitz A, Mangano DT. Renal dysfunction after myocardial revascularization: Risk factors, adverse outcomes, and hospital resource utilization. The Multicenter Study of Perioperative Ischemia Research Group. Ann Intern Med 1998; 128: 194-203.
36. Wendel H, Heller W, Gallimore M, Bantel H, Muller-Beissenhirtz H, Hoffmeister H-E. The prolonged activated clotting time (ACT) with aprotinin depends on the type of activator used for measurement. Blood Coagul Fibrinolysis 1993; 4: 41-5.
37. Wang J-S, Lin C-Y, Hung W-T, Karp R. Monitoring of heparin-induced anticoagulation with kaolin-activated clotting time in cardiac surgical patients treated with aprotinin. Anesthesiology 1992; 77: 1080-4.
38. Feindt PR, Walcher S, Volkmer I, Keller HE, Straub U, Huwer H, Seyfert UT, Petzold T, Gams E. Effects of high-dose aprotinin on renal function in aortocoronary bypass grafting. Ann Thorac Surg 1995; 60: 1076-80.
39. Fauli A, Gomar C, Campistol J, Alvarez L, Manig A, Matute P. Kidney-specific proteins in patients receiving aprotinin at high- and low-dose regimens during coronary artery bypass graft with cardiopulmonary bypass. Eur J Anaesthesiol 2005; 22: 666-71.
40. Lemmer Jr JH, Stanford W, Bonney SL, Chomka EV, Karp RB, Laub GW, Rumberger JA, Schaff HV. Aprotinin for coronary artery bypass grafting: effect on postoperative renal function. Ann Thorac Surg 1995; 59: 132-6.
41. Alderman EL, Levy JH, Rich JB, Nili M, Vidne B, Schaff H, Uretzky G, Pettersson G, Thiis JJ, Hantler CB, Chaitman B, Nadel A. Analyses of coronary graft patency after aprotinin use: Results from the International Multicenter Aprotinin Graft Patency Experience (IMAGE) trial. J Thorac Cardiovasc Surg 1998; 116: 716-30.
42. Cosgrove DI, Heric B, Lytle B, Taylor P, Novoa R, Golding L, Stewart R, McCarthy P, Loop F. Aprotinin therapy for reoperative myocardial revascularization: A placebo-controlled study. Ann Thorac Surg 1992; 54: 1031-8.
43. Lemmer Jr JH, Stanford W, Bonney SL, Breen JF, Chomka EV, Eldredge WJ, Holt WW, Karp RB, Laub GW, Lipton MJ, Schaff HV, Tatooles CJ, Rumberger JA. Aprotinin for coronary bypass operations: Efficacy, safety, and influence on early saphenous vein graft patency. A multicenter, randomized, double-blind, placebo-controlled study. J Thorac Cardiovasc Surg 1994; 107: 543-51; discussion 551-3.
44. Henry DA, Moxey AJ, Carless PA, O'Connell D, McClelland B, Henderson KM, Sly K, Laupacis A, Fergusson D. Anti-fibrinolytic use for minimising perioperative allogeneic blood transfusion. Cochrane Database Syst Rev 2001; CD001886.
45. Fiebig E, Busch M. Emerging infections in transfusion medicine. Clin Lab Med 2004; 24: 797-823.
46. Kuehnert M, Roth V, Haley N, Gregory K, Elder K, Schreiber G, Arduino M, Holt S, Carson L, Banerjee S, Jarvis W. Transfusion-transmitted bacterial infection in the United States, 1998 through 2000. Transfusion 2001; 41: 1493-9.
47. Toy P, Popovsky MA, Abraham E, Ambruso DR, Holness L, Kopko P, McFarland J, Nathens A, Silliman CC, Stroncek D. National Heart Lung and Blood Institute Working Group on TRALI: Transfusion-related acute lung injury: definition and review. Crit Care Med 2005; 33: 721-6.
48. Sazama K. Reports of 355 transfusion-associated deaths: 1976 through 1985. Transfusion 1990; 30: 583-90.
49. Andreu G, Morel P, Forestier F, Debeir J, Rebibo D, Janvier G, Herve P. Hemovigilance network in France: Organization and analysis of immediate transfusion incident reports from 1994 to 1998. Transfusion 2002; 42: 1356-64.
50. Sazama K. Transfusion errors: Scope of the problem, consequences, and solutions. Curr Hematol Rep 2003; 2: 518-21.
51. Lee T-H, Paglieroni T, Ohto H, Holland PV, Busch MP. Survival of donor leukocyte subpopulations in immunocompetent transfusion recipients: frequent long-term microchimerism in severe trauma patients. Blood 1999; 93: 3127-39.
52. Lee T-H, Paglieroni T, Utter G, Chafets D, Gosselin R, Reed W, Owings J, Holland PV, Busch MP. High-level long-term white blood cell microchimerism after transfusion of leukoreduced blood components to patients resuscitated after severe traumatic injury. Transfusion 2005; 45: 1280-90.
53. Collet J, Park D, Lesty C, Soria J, Montalescot G, Weisel J. Influence of fibrin network conformation and fibrin diameter on fibrinolysis speed: Dynamic and structural approaches by confocal microscopy. Arterioscler Thromb Vasc Biol 2000; 20: 1354-61.
54. Collet J, Lesty C, Montalescot G, Weisel J. Dynamic changes of fibrin architecture during fibrin formation and intrinsic fibrinolysis of fibrin-rich clots. J Biol Chem 2003; 278: 21331-5.
55. Collet JP, Montalescot G, Lesty C, Weisel JW. A structural and dynamic investigation of the facilitating effect of glycoprotein IIb/IIIa inhibitors in dissolving platelet-rich clots. Circ Res 2002; 90: 428-34.
56. Blomback B, Carlsson K, Fatah K, Hessel B, Procyk R. Fibrin in human plasma: Gel architectures governed by rate and nature of fibrinogen activation. Thromb Res 1994; 75: 521-38.
57. Weisel J, Veklich Y, Collet J, Francis C. Structural studies of fibrinolysis by electron and light microscopy. Thromb Haemost 1999; 82: 277-82.
58. Vlahakes GJ. The value of phase 4 clinical testing. N Engl J Med 2006; 354: 413-5.